2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Carbonic Anhydrase

Carbonic Anhydrase

Carbonate dehydratase

Carbonic Anhydrase

Related Products

PDF 0.73 MB

Carbonic anhydrase (CA) is a zinc-containing enzyme that catalyzes the reversible hydration of carbon dioxide: CO2 + H2O ⇋ HCO3- + H+. Eight genetically distinct carbonic anhydrase enzyme families (α-, β-, γ- δ-, ζ-, η-, θ- and ι- CAs) were described to date. Carbonic anhydrases are involved in numerous physiological and pathological processes. Many of them are important therapeutic targets with the potential to be inhibited to treat a range of disorders including oedema, glaucoma, obesity, cancer, epilepsy, and osteoporosis.

The carbonic anhydrase reaction is involved in many physiological and pathological processes, including respiration and transport of CO2 and bicarbonate between metabolizing tissues and lungs; pH and CO2 homeostasis; electrolyte secretion in various tissues and organs; biosynthetic reactions (such as gluconeogenesis, lipogenesis, and ureagenesis); bone resorption; calcification; and tumorigenicity. α-CAs are Zn2+ metalloproteins expressed in animals, vertebrates, prokaryotes, fungi, algae, protozoa, and plants. Sixteen mammalian α-CA isoforms are known to be involved in many diseases such as glaucoma, edema, epilepsy, obesity, hypoxic tumors, neuropathic pain, arthritis, neurodegeneration, etc.

Carbonic Anhydrase Isoform Specific Products:

Carbonic Anhydrase Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-147663
    hCAIX-IN-6
    Compounds 6b and 14g showed significant inhibitory effect on tumor related subtype HCA IX with low nanomolar potency, while 6k was effective on HCA XII. Compounds 6b, 14g and 6k can be considered as the leading molecules for the development of future cancer therapeutic drugs based on new mechanisms of action.
    hCAIX-IN-6
  • HY-19213
    L-693612
    		Inhibitor
    L-693612 (Compd 1) is an orally active and topical carbonic anhydrase inhibitor.
    L-693612
  • HY-169163
    BChE-IN-36
    		Activator
    hBChE-IN-4 (compound 40) is a potent hCA activator and BChE inhibitor with KA values of 266, 76.9, 918, 893, 98.0 nM for hCA I, hCA II, hCA IV, hCA VB, hCA VII, IC50 values of 72.1, 4.2 nM for eeAChE, eqBChE, respectively. hBChE-IN-4 shows no cytotoxicity. hBChE-IN-4 shows potent procognitive effects. hBChE-IN-4 has the potential for the research of neurodegenerative diseases and other neuropsychiatric disorders.
    BChE-IN-36
  • HY-152141
    hCAII-IN-9
    		Inhibitor
    hCAII-IN-9 is a potent carbonic anhydrase inhibitor with IC50s of 1.18 μM (hCA II), 0.17 μM (hCA IX), and 2.99 μM (hCA XII), respectively. hCAII-IN-9 has no blood-brain barrier permeability.
    hCAII-IN-9
  • HY-146983
    hCAIX-IN-3
    		Inhibitor
    hCAII-IN-3 (compound 7e) is a potent and selective inhibitor of carbonic anhydrase (CA II/IX) with Kis of 124.2 and 30.5 nM, respectively. hCAII-IN-3 has the potential for the research of cancer diseases.
    hCAIX-IN-3
  • HY-150977
    β-Glucuronidase/hCAII-IN-2
    		Inhibitor
    β-Glucuronidase/hCAII-IN-2 (Compound 12e) is a potent β-glucuronidase and hCA II inhibitor with an IC50 of 670.7 μM and 21.77 μM, respectively.
    β-Glucuronidase/hCAII-IN-2
  • HY-150976
    β-Glucuronidase/hCAII-IN-1
    		Inhibitor
    β-Glucuronidase/hCAII-IN-2 (Compound 12e) is a potent β-glucuronidase and hCA II inhibitor with an IC50 of 440.1 μM and 4.91 μM, respectively.
    β-Glucuronidase/hCAII-IN-1
  • HY-175245
    hCA-IN-1
    		Inhibitor
    hCA-IN-1 (Compound 5u) is an hCA inhibitor with Ki values of 159.2, 4.8, 15.5, and 2 nM against hCA I, hCA II, hCA IX, and hCA XII, respectively. hCA-IN-1 exhibits broad-spectrum anticancer activity against melanoma, breast, and colon cancer cells. ADME predictions indicate that hCA-IN-1 has good solubility and oral bioavailability. hCA-IN-1 can be used in tumor research.
    hCA-IN-1
  • HY-126117
    (+)-Xylariamide A
    		Inhibitor
    (+)-Xylariamide A (compound 6b) is a mycobacterial and fungal carbonic anhydrase probe with inhibitory activity against pathogen β-carbonic anhydrases.
    (+)-Xylariamide A
  • HY-155694
    hCA/VEGFR-2-IN-1
    		Inhibitor
    hCA/VEGFR-2-IN-1 (compound 13a) is a potent dual Carbonic Anhydrase(CA) IX/XII with Ki values of 4.7 nM and 8.3 nM for hCA XII and hCA IX, respectively. hCA/VEGFR-2-IN-1 (compound 13a) is a potent VEGFR-2 inhibitor with IC50 values 26.3 nM. hCA/VEGFR-2-IN-1 has anticancer activity.
    hCA/VEGFR-2-IN-1
  • HY-147664
    hCAXII-IN-1
    These compounds show selective inhibition on tumor related subtypes HCA IX and XII, and are also considered as the leading molecules for the development of future cancer therapeutic drugs based on new mechanisms of action.
    hCAXII-IN-1
  • HY-163414
    hCAIX/XII-IN-11
    		Inhibitor
    hCAIX/XII-IN-11 (Compound 6c) is an inhibitor of hCA IX and hCA XII with a Ki value of 0.7 μM for both the isoforms. hCAIX/XII-IN-11 can be used for anticancer research.
    hCAIX/XII-IN-11
  • HY-172816
    Carbonic anhydrase inhibitor 32
    		Inhibitor
    Carbonic anhydrase inhibitor 32 (compound 5B) is an orally active and selective hCA (Carbonic anhydrase ) II/VII inhibitor with the Ki values of 6.3 nM, 10.1 nM and 681 nM for hCA II, hCA VII and hCA I,respectively. Carbonic anhydrase inhibitor 32 shows neuroprotective and anticonvulsant potential by reducing mTOR activation, and raising hippocampus KCC2 levels.
    Carbonic anhydrase inhibitor 32
  • HY-150570
    Carbonic anhydrase inhibitor 14
    		Inhibitor
    Carbonic anhydrase inhibitor 14 (Compound 8b) is a carbonic anhydrase (CA) inhibitor with Ki values of 1203, 99.7, 9.4 and 27.7 nM against hCA I, hCA II, hCA IX and hCA XII, respectively. Carbonic anhydrase inhibitor 14 can also inhibit CDK2 with an IC50 of 20.3 μM. Carbonic anhydrase inhibitor 14 shows antitumor activity.
    Carbonic anhydrase inhibitor 14
  • HY-B1364
    Quinethazone
    		Inhibitor
    Quinethazone is an orally active diuretic agent and is also a weak inhibitor of carbonic anhydrase. Quinethazone can be used for hypertension research.
    Quinethazone
  • HY-142853
    Carbonic anhydrase inhibitor 3
    		Inhibitor
    Carbonic anhydrase inhibitor 3 (compound 11g) is a carbonic anhydrase II inhibitor. Carbonic anhydrase inhibitor 3 reduces the intraocular pressure in glaucomatous rabbits.
    Carbonic anhydrase inhibitor 3
  • HY-168604
    CA Ⅱ-IN-1
    		Inhibitor
    CA Ⅱ-IN-1 (compound 2i) is a CA Ⅱ isozyme inhibitor, with IC50 of 0.44 µM. CA Ⅱ-IN-1 can be used for metabolic studies.
    CA Ⅱ-IN-1
  • HY-B0109AS1
    Dorzolamide-d5(hydrochloride)
    		Inhibitor
    Dorzolamide-d5(hydrochloride) (L671152 hydrochloride-d5) is deuterium labeled Dorzolamide (hydrochloride). Dorzolamide (L671152) hydrochloride is a potent carbonic anhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity.
    Dorzolamide-d<sub>5</sub>(hydrochloride)
  • HY-B0235R
    Trichlormethiazide (Standard)
    		Inhibitor
    Trichlormethiazide (Standard) is the analytical standard of Trichlormethiazide. This product is intended for research and analytical applications. Trichlormethiazide is an orally active thiazide diuretic, with antihypertensive effect. Trichlormethiazide increases urine volume (UV), Na and K excretion and tends to improve the depressed creatinine clearance (CCRE) in acute renal failure rats model.
    Trichlormethiazide (Standard)
  • HY-146819
    CAIX/CAXII-IN-1
    Compound 9 is the most effective against tumor specific Ca ix/ca XII (ki=29.1 and 8.8 nm), so it is possible to evaluate its cytotoxicity and selectivity to HepG-2, HCT-116 and MCF-7 cancer cell lines in vitro, and its IC50 values to tumor cells are 1.78, 1.94 and 3.07, respectively μ M. It showed that it had obvious cytotoxicity.
    CAIX/CAXII-IN-1
Cat. No. Product Name / Synonyms Species Source
Carbonic Anhydrase Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.